Literature DB >> 14987309

Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern.

A Helbling1, T Hurni, U R Mueller, W J Pichler.   

Abstract

BACKGROUND: Diagnosis of anaphylaxis is clinically based and usually straightforward. However, data on the epidemiology of anaphylaxis, particularly the most profound and life-threatening form such as anaphylactic shock are limited and thought to be under-reported.
OBJECTIVE: The primary aim of this study was to investigate the incidence and the causes of severe anaphylaxis with circulatory signs in the Canton Bern, which comprises about 940 000 inhabitants or approximately one-seventh of the population of Switzerland.
METHODS: During a 3-year period, 1 January 1996 to 31 December 1998, all medical records (7739 documents) from the two allergy clinics of the Canton Bern have been reviewed. In addition, all seven board-certified specialists of the Foederatio Medicorum Helveticorum (FMH) in Allergology and Clinical Immunology of this Canton as well as all 17 hospitals with emergency units of this area have been contacted for cases with an anaphylactic event not referred to the allergy clinics.
RESULTS: Overall, 226 individuals, 106 females (47%) with a mean age of 41 years (range, 5-74 years) and 120 males (53%) with a mean age of 38 years (8 months-83 years) were diagnosed as having presented generalized, life-threatening anaphylaxis with circulatory symptoms. Altogether, these patients experienced 246 episodes of severe systemic reactions. In addition, death due to anaphylaxis occurred in three subjects. The annual incidence of anaphylaxis per 100 000 inhabitants per year ranged between 7.9 and 9.6 cases. Hymenoptera stings (58.8%), drugs (18.1%), and foods (10.1%) were the most commonly identified culprits for anaphylaxis. In 5.3% of all anaphylactic events, the cause could not be identified.
CONCLUSION: The incidence rate of severe life-threatening anaphylaxis with circulatory signs in the Canton Bern, Switzerland, with 7.9-9.6 per 100 000 inhabitants per year is comparable to the findings of other epidemiological investigations. In most events, a causal agent or allergen could be identified by a careful allergological examination.

Entities:  

Mesh:

Year:  2004        PMID: 14987309     DOI: 10.1111/j.1365-2222.2004.01882.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  37 in total

Review 1.  H1-antihistamines for the treatment of anaphylaxis with and without shock.

Authors:  A Sheikh; V m ten Broek; S G A Brown; F E R Simons
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Case fatality and population mortality associated with anaphylaxis in the United States.

Authors:  Larry Ma; Theodore M Danoff; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2013-12-14       Impact factor: 10.793

3.  Allergy-induced preterm labor after the ingestion of shellfish.

Authors:  Roberto Romero; Juan Pedro Kusanovic; Hernan Muñoz; Ricardo Gomez; Ronald F Lamont; Lami Yeo
Journal:  J Matern Fetal Neonatal Med       Date:  2010-04

4.  Kounis syndrome secondary to gadolinium contrast agent.

Authors:  Waiel Abusnina; Mena Shehata; Mahmoud Abouzid; Malesa Price; Fuad Zeid
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-04-23

Review 5.  [Management of anaphylaxis. Part 1: Causes and pathophysiology].

Authors:  A Glowania; U Goebel; L Klimek
Journal:  HNO       Date:  2012-11       Impact factor: 1.284

Review 6.  NIAID-sponsored 2010 guidelines for managing food allergy: applications in the pediatric population.

Authors:  A Wesley Burks; Stacie M Jones; Joshua A Boyce; Scott H Sicherer; Robert A Wood; Amal Assa'ad; Hugh A Sampson
Journal:  Pediatrics       Date:  2011-10-10       Impact factor: 7.124

Review 7.  Epidemiology and risk factors for drug allergy.

Authors:  Bernard Y-H Thong; Teck-Choon Tan
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

Review 8.  [Anaphylaxis in childhood and adolescence].

Authors:  H Ott; S Lehmann; G Wurpts; H-F Merk; A Viardot-Helmer; E Rietschel; J M Baron
Journal:  Hautarzt       Date:  2007-12       Impact factor: 0.751

9.  Anaphylaxis in referred pediatric patients: demographic and clinical features, triggers, and therapeutic approach.

Authors:  Liliane F A De Swert; Dominique Bullens; Marc Raes; Anna-Maria Dermaux
Journal:  Eur J Pediatr       Date:  2008-01-17       Impact factor: 3.183

10.  [Management of anaphylaxis : part 2: treatment and emergency equipment].

Authors:  L Klimek; U Goebel; A Glowania
Journal:  HNO       Date:  2012-12       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.